Treatment Outcome of Burkitt's Lymphoma in Adolescents and Adults: A Retrospective Study

Abstract

Introduction Burkitt's lymphoma (BL) is a highly aggressive B cell non-Hodgkin lymphoma (NHL) having three distinct subtypes: endemic, sporadic, and immunodeficiency-associated BL. Sporadic BL accounts for only 1 to 2% of adult NHL.

Objectives The objective of this article was to study the clinical profile and treatment outcome of patients with BL.

Materials and Methods This was a retrospective study of 60 patients with BL conducted in the department of medical oncology at a tertiary cancer center in India during a 10-year period. Patients with BL/leukemia above 14 years of age diagnosed during the study period were included and their clinical presentation, treatment details, and outcome were studied.

Results Among 60 cases with BL, there were 41 males and 19 females. The median age at presentation was 42 years (range: 14–81 years). The main symptoms were lymphadenopathy, abdominal pain, and abdominal distension. Two patients each had paraparesis, breast lump, and jaw swelling and one patient had involvement of the cervix. Thirteen patients had features of tumor lysis at presentation. The Ann Arbor stage was I in 17, II in 16, III in 5, and IV in 22. Fifty-five patients received combination chemotherapy that included hyper-cyclophosphamide, vincristine, adriamycin, dexamethasone ± rituximab (hyper-CVAD ± R; 35), cyclophosphamide, adriamycin, vincristine, prednisolone/ cyclophosphamide, vincristine, prednisolone ± rituximab CHOP ± R (13), Berlin-Frankfurt-Munich protocol (4), and others (3). Thirty-four patients attained remission, 13 patients had progressive disease, and 8 patients died during chemotherapy. At a median follow-up of 113 months, 58% patients were alive.

Conclusions BL accounts for 1.57% of NHL above the age of 14 years with male preponderance. Intensive, short-duration chemotherapy is the standard treatment. Treatment with hyper-CVAD ± R gives 8-year progression-free survival and overall survival (OS) of 60%. Treatment with CHOP ± R is an alternative option in elderly frail patients with an 8-year OS of 46%.

Keywords

Burkitt's lymphoma - non-Hodgkin lymphoma - clinical characteristics - treatment outcome

Authors' Contributions

S.M.T. was involved in design, literature search, data acquisition, data analysis, statistical analysis, and manuscript preparation. G.N. contributed to conceptualization, designing, data acquisition, data analysis, manuscript preparation, manuscript editing, and manuscript review. A.T.M. helped in data acquisition and manuscript editing. S.G.N., P.N.P., and R.A.N. contributed to data acquisition. Jagathnath Krishna did statistical analysis.

Publikationsverlauf

Artikel online veröffentlicht:
24. April 2023

• References

• 1 Jaffe ES, Harris NL, Stein H, Vardiman JW. . Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001
• 2 Jaffe ES. The 2008 WHO classification of lymphomas: implications for clinical practice and translational research. Hematology (Am Soc Hematol Educ Program) 2009; 1: 523-531
• 3 Boerma EG, van Imhoff GW, Appel IM, Veeger NJ, Kluin PM, Kluin-Nelemans JC. Gender and age-related differences in Burkitt lymphoma--epidemiological and clinical data from The Netherlands. Eur J Cancer 2004; 40 (18) 2781-2787
• 4 Wästerlid T, Jonsson B, Hagberg H, Jerkeman M. Population based study of prognostic factors and treatment in adult Burkitt lymphoma: a Swedish Lymphoma Registry study. Leuk Lymphoma 2011; 52 (11) 2090-2096
• 5 Cheson BD, Pfistner B, Juweid ME. et al; International Harmonization Project on Lymphoma. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25 (05) 579-586
• 6 Schulz TF, Boshoff CH, Weiss RA. HIV infection and neoplasia. Lancet 1996; 348 (9027): 587-591
• 7 Mbulaiteye SM, Biggar RJ, Bhatia K, Linet MS, Devesa SS. Sporadic childhood Burkitt lymphoma incidence in the United States during 1992-2005. Pediatr Blood Cancer 2009; 53 (03) 366-370
• 8 Teras LR, DeSantis CE, Cerhan JR, Morton LM, Jemal A, Flowers CR. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin 2016; 66 (06) 443-459
• 9 Nair R, Arora N, Mallath MK. Epidemiology of non-Hodgkin's lymphoma in India. Oncology 2016; 91 (1, Suppl 1): 18-25
• 10 Kelly GL, Rickinson AB. Burkitt lymphoma: revisiting the pathogenesis of a virus-associated malignancy. Hematology (Am Soc Hematol Educ Program) 2007; 1: 277-284 PubMed
• 11 Mead GM, Sydes MR, Walewski J. et al; UKLG LY06 collaborators. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. Ann Oncol 2002; 13 (08) 1264-1274
• 12 Mead GM, Barrans SL, Qian W. et al; UK National Cancer Research Institute Lymphoma Clinical Studies Group; Australasian Leukaemia and Lymphoma Group. A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial). Blood 2008; 112 (06) 2248-2260
• 13 Arora N, Manipadam MT, Nair S. Frequency and distribution of lymphoma types in a tertiary care hospital in South India: analysis of 5115 cases using the World Health Organization 2008 classification and comparison with world literature. Leuk Lymphoma 2013; 54 (05) 1004-1011
• 14 Saleh K, Michot JM, Camara-Clayette V, Vassetsky Y, Ribrag V. Burkitt and Burkitt-Like lymphomas: a systematic review. Curr Oncol Rep 2020; 22 (04) 33
• 15 Lee EJ, Petroni GR, Schiffer CA. et al. Brief-duration high-intensity chemotherapy for patients with small noncleaved-cell lymphoma or FAB L3 acute lymphocytic leukemia: results of cancer and leukemia group B study 9251. J Clin Oncol 2001; 19 (20) 4014-4022
• 16 Wilson WH, Grossbard ML, Pittaluga S. et al. Dose-adjusted EPOCH chemotherapy for untreated large B-cell lymphomas: a pharmacodynamic approach with high efficacy. Blood 2002; 99 (08) 2685-2693
• 17 Thomas DA, Faderl S, O'Brien S. et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006; 106 (07) 1569-1580
• 18 Sengar M, Akhade A, Nair R. et al. A retrospective audit of clinicopathological attributes and treatment outcomes of adolescent and young adult non-Hodgkin lymphomas from a tertiary care center. Indian J Med Paediatr Oncol 2011; 32 (04) 197-203
• 19 Wästerlid T, Brown PN, Hagberg O. et al. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group. Ann Oncol 2013; 24 (07) 1879-1886
• 20 Longo DL, Duffey PL, Jaffe ES. et al. Diffuse small noncleaved-cell, non-Burkitt's lymphoma in adults: a high-grade lymphoma responsive to ProMACE-based combination chemotherapy. J Clin Oncol 1994; 12 (10) 2153-2159
• 21 Thomas DA, Cortes J, O'Brien S. et al. Hyper-CVAD program in Burkitt's-type adult acute lymphoblastic leukemia. J Clin Oncol 1999; 17 (08) 2461-2470
• 22 Magrath I, Adde M, Shad A. et al. Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 1996; 14 (03) 925-934
• 23 Lacasce A, Howard O, Lib S. et al. Modified Magrath regimens for adults with Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity. Leuk Lymphoma 2004; 45 (04) 761-767
• 24 Patekar M, Gogia A, Tiwari A. et al. Adult Burkitt lymphoma: an institutional experience with a uniform chemotherapy protocol. South Asian J Cancer 2018; 7 (03) 195-199
• 25 Rizzieri DA, Johnson JL, Byrd JC. et al; Alliance for Clinical Trials In Oncology (ACTION). Improved efficacy using rituximab and brief duration, high intensity chemotherapy with filgrastim support for Burkitt or aggressive lymphomas: cancer and Leukemia Group B study 10 002. Br J Haematol 2014; 165 (01) 102-111